Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    altimmune | Covid-19
Previous Study | Return to List | Next Study

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04442230
Recruitment Status : Not yet recruiting
First Posted : June 22, 2020
Last Update Posted : July 15, 2020
Sponsor:
Information provided by (Responsible Party):
Altimmune, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.

Condition or disease Intervention/treatment Phase
Coronavirus Infection Biological: NasoVAX Other: Placebo Phase 2

Detailed Description:

After being informed about the study and potential risks, all patient volunteers that have given written informed consent will undergo screening to determine eligibility for study entry. If the patient qualifies for the study, they will be randomized in a double-blind manner in a 1:1 ratio to receive NasoVAX or placebo. On the same day of qualifying into the study, the patient will be administered the investigational drug (either NasoVAX or placebo).

The patient will return home for the remainder of the study. During this period, the patient will be monitored remotely by the study center for clinical status. The patient will also be contacted by study center personnel by telephone to ask about use of any medications and changes in health including information about any hospitalization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Estimated Study Start Date : July 2020
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NasoVAX
Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
Biological: NasoVAX
NasoVAX consists of replication-deficient adenovirus vectors in suspension

Placebo Comparator: Placebo
Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
Other: Placebo
Normal saline




Primary Outcome Measures :
  1. Proportion of patients with clinical worsening [ Time Frame: Day 1 to Day 14 ]
    Decrease from baseline in mean resting SpO2


Secondary Outcome Measures :
  1. Maximal severity of COVID-19 after treatment [ Time Frame: Day 1 to Day 42 ]
    Proportion of patients requiring hospitalization

  2. All-cause mortality [ Time Frame: Day 1 to Day 42 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to provide informed consent (Patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted).
  2. Men and women 35 years of age and older
  3. Early COVID-19, defined as fever (oral temperature ≥ 100.4 degrees F), cough or shortness of breath, with onset of these symptoms within 48 hours, and confirmation of SARS-CoV-2 infection by a polymerase chain reaction (PCR)-based diagnostic within the previous 24 hours
  4. Resting SpO2 ≥ 96.0% on room air on two successive measurements
  5. For women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause])

    • Negative urine pregnancy test at Screening
    • Willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug
  6. For men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug
  7. Ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

Exclusion Criteria:

  1. Pregnant or lactating women or planning to conceive a child during the next 3 months
  2. Resting respiratory rate >20 breaths/min on room air or resting pulse rate ≥ 125 beats per minute
  3. A rapidly worsening course that in the opinion of the Investigator or treating medical practitioner would lead to hospitalization within the next 24-48 hours
  4. Any chronic pulmonary disease, including chronic obstructive pulmonary disease and asthma, or other respiratory diseases that could exacerbate independent of COVID-19
  5. The following risk factors for severe COVID-19 (Cohorts 1 and 2 only) (Center for Disease Control 2020), which based on ongoing review of efficacy and safety data, the DMC may remove part or all of these risk factors if preliminary data show no signal for adverse or paradoxical effects:

    1. Severe obesity, defined as body mass index ≥ 40 kg/m2
    2. History of:

      • Severe cardiovascular disease, including but not limited to congestive heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, or pulmonary hypertension
      • Diabetes mellitus
      • Chronic or current vaping or cigarette smoking
      • Chronic kidney disease requiring dialysis
      • Chronic liver disease, including but not limited to chronic viral hepatitis, non-alcoholic steatohepatitis, or cirrhosis of any cause
      • Hemoglobin disorder, including sickle cell disease and thalassemia
  6. History of Bell's Palsy
  7. Nasal conditions that might affect the suitability of intranasal medication, such as a history of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or nasal surgery other than cosmetic rhinoplasty.
  8. Use of hydroxychloroquine within the past 4 months, chloroquine with the past 9 months, or other investigational agents for COVID-19 within the past 30 days
  9. History of conditions associated with immunocompromise, including but not limited to poorly controlled HIV, or treatments known to affect the immune system, including but not limited to oral or intravenous corticosteroids, alkylating drugs, antimetabolites, cytotoxic drugs, radiation, immune-modulating biologics (including interleukin [IL]-6, IL-12, Janus kinase inhibitors or antagonists), and cancer treatments, within 30 days of Screening, or anticipated use within 6 months following participation in this study
  10. Any medical, psychiatric, or social condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety (including reactogenicity), or a patient's ability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04442230


Contacts
Layout table for location contacts
Contact: Christine Orlando (240) 654-1450 corlando@altimmune.com
Contact: Staci Steele ssteele@altimmune.com

Sponsors and Collaborators
Altimmune, Inc.
Layout table for additonal information
Responsible Party: Altimmune, Inc.
ClinicalTrials.gov Identifier: NCT04442230    
Other Study ID Numbers: ALT-601-201
First Posted: June 22, 2020    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Altimmune, Inc.:
COVID-19
SARS-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Infection
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases